Controlling Neuroinflammation in Alzheimers Disease

Grant number: 1044714 | Funding period: 2013 - 2015

Completed

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, with 269,000 Australians currently diagnosed with AD and is expected to soar to about 981,000 by 2050. AD accounts for greater than 60% of all cases of dementia. This grant investigates the role that neuroinflammation plays in the progression and exacerbation of AD and will identify new therapeutic strategies to combat this insidious disease.

Related publications (3)

Deletion of the type-1 interferon receptor in APPSWE/PS1ΔE9 mice preserves cognitive function and alters glial phenotype

MR Minter, Z Moore, M Zhang, KM Brody, NC Jones, SR Shultz, JM Taylor, PJ Crack

2016-07-11

A neuro-inflammatory response is evident in Alzheimer's disease (AD), yet the precise mechanisms by which neuro-inflammation influ..

The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease

MR Minter, JM Taylor, PJ Crack

2016-02-01

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia. Deposition of amyloid-β..

Ablation of type-1 IFN signaling in hematopoietic cells confers protection following traumatic brain injury

IP Karve, M Zhang, M Habgood, T Frugier, KM Brody, M Sashindranath, C Joakim Ek, S Chappaz, BT Kile, D Wright, H Wang, L Johnston, M Daglas, RC Ates, RL Medcalf, JM Taylor, PJ Crack

2016-01-01

Type-1 interferons (IFNs) are pleiotropic cytokines that signal through the type-1 IFN receptor (IFNAR1). Recent literature has im..

University of Melbourne Researchers

Peter Crack